SEC Company Response from NRX Pharmaceuticals, (NRXP) — Dec 18, 2025
NRX Pharmaceuticals, Inc.
Date: Dec. 18, 2025 · CIK: 0001719406 · Accession: 0001437749-25-038319
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-288205
Letter
VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Attention: Jason Drory NRx Pharmaceuticals, Inc. Registration Statement on Form S-3/A File No. 333-288205 Request for Effectiveness
Dear Mr. Drory:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, NRx Pharmaceuticals, Inc. respectfully requests that the effective date of the above-referenced Registration Statement on Form S-3/A (the “Registration Statement”) be accelerated so as to permit it to become effective at 5:00 p.m. Washington D.C. time on December 22, 2025, or as soon thereafter as practicable.
Please call Kevin J. Roggow of Cozen O’Connor at (212) 908-1294 to provide notice of the effectiveness of the Registration Statement.
* * *
[ Signature Page Follows]
Very truly yours,
NRx Pharmaceuticals, Inc.
Show Raw Text
CORRESP 1 filename1.htm nrxp20251218_corresp.htm NRx Pharmaceuticals, Inc. 1201 Orange Street, Suite 600 Wilmington, DE 19801 December 18, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jason Drory Re: NRx Pharmaceuticals, Inc. Registration Statement on Form S-3/A File No. 333-288205 Request for Effectiveness Dear Mr. Drory: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, NRx Pharmaceuticals, Inc. respectfully requests that the effective date of the above-referenced Registration Statement on Form S-3/A (the “Registration Statement”) be accelerated so as to permit it to become effective at 5:00 p.m. Washington D.C. time on December 22, 2025, or as soon thereafter as practicable. Please call Kevin J. Roggow of Cozen O’Connor at (212) 908-1294 to provide notice of the effectiveness of the Registration Statement. * * * [ Signature Page Follows] Very truly yours, NRx Pharmaceuticals, Inc. By: /s/ Jonathan Javitt Name: Jonathan Javitt Title: Interim Chief Executive Officer cc: Kevin J. Roggow Cozen O ’ Connor [ Signature Page to Acceleration Request Letter ] 2